PDF   Print   View All
February 24, 2005
Hemispherx Biopharma's Alferon N® Highlighted as Potential New Therapy for Avian Influenza on CNBC's "Closing Bell"
“Battling the Bird Flu” Segment Features Microcap Company as Contender in the Avian Flu Drug Manufacturing Race

Philadelphia, PA, Thursday, February 24, 2005: Hemispherx Biopharma, Inc. (Amex:HEB) was highlighted on CNBC’s “Closing Bell” program yesterday in a segment on Avian Flu. Pharmaceuticals reporter Mike Huckman reported that the World Health Organization has predicted that the Avian Flu threatens to spread around the world and infect millions of people. Huckman focused on Hemispherx Biopharma as one of a few companies with a plausible potential treatment for the deadly virus.

The segment discussed the lack of any currently available treatment for Avian Flu in the marketplace, as well as the potential for a “global pandemic” anticipated by many if the virus mutates and transfers from animals to humans. Hemispherx is a drug manufacturer with two different approaches to battling Avian Flu: The company has tested Alferon N in the food and water of birds raised as poultry crops (where the virus may breed) and found it reduces mortality rates and contributes to a healthier bird population. Additionally, Hemispherx is set to begin drug trials in humans next month.

To obtain a CD of the segment, email your postal contact information to sschroeder@investorrelationsgroup.com

Note: The anticipated clinical trials in human volunteers (to be conducted in both the U.S. and Asia) are designed to determine whether Alferon N, delivered in a new, experimental oral drug delivery format, can resuscitate the broad-spectrum antiviral genes, which are shut down by dreaded viruses such as avian flu and smallpox. Recent studies indicate that these disabled genes may have led to the pandemic in 1918/1919, which killed millions worldwide.

About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities. Its flagship products include Alferon N® and the experimental antiviral products, Ampligen® and Oragens(TM). These novel Alferon-N proteins, commercially available for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its four major technology platforms include large-and small-agent components for potential treatment of various chronic viral infections, and are being developed with various corporate, governmental and academic collaborators worldwide. Hemispherx has more than 200 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N®) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6369

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon N do not imply that the product will ever be specifically approved commercially for these other treatment indications including avian flu.